Tibet Duo Rui Pharmaceutical
301075
Alnera Aluminium
301613
ChengDu Sheng Nuo Biotec
688117
4
THEC
833509
5
Nanjing Railway New Technology
301016
CN Stock MarketDetailed Quotes
300146 Byhealth Co.,Ltd
- 11.72
- -0.05-0.42%
Trading Mar 31 09:57 CST
19.93BMarket Cap30.52P/E (TTM)
11.79High11.67Low26.97KlotVolume11.72Open11.77Pre Close31.63MTurnover0.24%Turnover Ratio30.52P/E (Static)1.70BShares17.7752wk High1.80P/B13.24BFloat Cap10.6552wk Low14.12Limit Up1.13BShs Float36.13Historical High9.42Limit Down1.02%Amplitude-1.15Historical Low0.90Dividend TTM11.73Avg Price14.50KlotAsk7.68%Div YieldTTM100Lot Size11.81KlotBid
Byhealth Co.,Ltd Key Stats
All
YOY
| (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -27.30%6.84B | -26.33%5.73B | -17.56%4.61B | -14.87%2.65B | 19.66%9.41B | 26.34%7.78B | 32.58%5.6B | 36.30%3.11B | 5.79%7.86B | 2.18%6.16B |
| Operating revenue | -27.30%6.84B | -26.33%5.73B | -17.56%4.61B | -14.87%2.65B | 19.66%9.41B | 26.34%7.78B | 32.58%5.6B | 36.30%3.11B | 5.79%7.86B | 2.18%6.16B |
| Other operating revenue | 69.46%57.66M | ---- | 107.19%31.1M | ---- | 2.97%34.02M | ---- | 0.13%15.01M | ---- | -40.92%33.04M | ---- |
| Total operating cost | -19.67%6.02B | -14.26%4.8B | -5.09%3.6B | -2.93%1.78B | 19.89%7.5B | 24.96%5.6B | 28.60%3.8B | 27.85%1.83B | 12.02%6.25B | 10.23%4.48B |
| Operating cost | -22.16%2.28B | -22.13%1.84B | -12.67%1.45B | -13.67%796.4M | 17.38%2.93B | 22.81%2.36B | 28.37%1.66B | 33.12%922.5M | -1.13%2.49B | -3.96%1.92B |
| Operating tax surcharges | -40.40%55.49M | -41.62%42.08M | -39.70%32.18M | -57.10%11.79M | 21.13%93.11M | 22.41%72.07M | 30.57%53.37M | 29.44%27.48M | 3.57%76.86M | -2.73%58.88M |
| Operating expense | -21.45%3.03B | -11.07%2.43B | -0.37%1.82B | 7.87%825.58M | 21.77%3.86B | 30.83%2.73B | 35.51%1.83B | 29.75%765.38M | 27.87%3.17B | 27.26%2.09B |
| Administration expense | 12.74%557.13M | 15.04%402.36M | 23.49%253.87M | 22.50%125.6M | 26.40%494.18M | 6.16%349.77M | -4.32%205.58M | -2.36%102.53M | 0.79%390.97M | 15.65%329.48M |
| Financial expense | 11.87%-49.12M | 27.88%-28.57M | 22.89%-25.5M | 11.43%-12.38M | -54.67%-55.74M | -71.86%-39.62M | -167.24%-33.07M | -84.51%-13.98M | -17.73%-36.04M | -7.79%-23.05M |
| -Interest expense (Financial expense) | 193.16%12.15M | 424.83%10.85M | 1,253.12%3.66M | 1,124.98%1.86M | 88.21%4.15M | -3.92%2.07M | -82.83%270.12K | -81.71%152.16K | -78.37%2.2M | -73.48%2.15M |
| -Interest Income (Financial expense) | 11.90%-57.73M | -3.52%-43.04M | 4.86%-31.48M | 22.46%-13.9M | -58.99%-65.53M | -61.92%-41.57M | -96.48%-33.08M | -67.87%-17.92M | 13.13%-41.21M | 23.60%-25.68M |
| Research and development | -17.12%148.63M | -5.73%116.33M | -13.47%69.78M | 11.13%31.4M | 13.15%179.33M | 18.38%123.4M | 23.51%80.65M | -10.27%28.26M | 5.45%158.5M | 6.97%104.25M |
| Credit Impairment Loss | 295.34%2.64M | 74.65%-6.83M | 35.34%-13.36M | 5.45%-12.75M | 52.73%-1.35M | -63.56%-26.93M | -60.94%-20.66M | -11.45%-13.49M | 57.44%-2.85M | 4.55%-16.47M |
| Asset Impairment Loss | -243.02%-43.04M | -17.35%-10.4M | -19.89%-8.42M | -672.29%-3.15M | 34.08%-12.55M | 22.66%-8.87M | 21.73%-7.02M | 57.44%-407.47K | -1.61%-19.03M | -0.80%-11.46M |
| Other net revenue | -95.74%6.75M | 14.68%89.74M | 45.12%71.69M | 117.39%22.37M | 21,062.01%158.31M | -12.80%78.25M | 383.40%49.4M | 140.06%10.29M | -99.58%748.09K | 214.18%89.74M |
| Fair value change income | -44.56%28.39M | 635.15%38.03M | 613.16%34.36M | 114.68%2.53M | 128.79%51.21M | 90.89%-7.11M | 91.48%-6.7M | 65.95%-17.26M | -357.66%-177.85M | -195.19%-78.04M |
| Invest income | -125.21%-23.79M | -55.16%49.11M | -44.40%41.58M | -35.98%23.62M | -50.48%94.37M | -40.74%109.53M | 0.21%74.78M | 13.52%36.9M | 59.13%190.55M | 150.38%184.83M |
| -Including: Investment income associates | -131.58%-98.85M | ---- | ---- | ---- | -295.05%-42.68M | ---- | ---- | ---- | -171.69%-10.8M | ---- |
| Asset deal income | 13,496.37%14.44M | -118.32%-181.27K | -125.55%-211.58K | -100.00%0.35 | 102.72%106.23K | 22.73%989.29K | 63.70%828.16K | -50.43%252.79K | -3,434.11%-3.91M | 687.17%806.06K |
| Other revenue | 5.94%28.1M | 88.13%20.01M | 117.07%17.75M | 182.31%12.12M | 91.53%26.52M | 5.62%10.64M | 4.21%8.18M | -14.75%4.29M | -1.98%13.85M | 3.82%10.07M |
| Operating profit | -60.19%823.51M | -54.73%1.03B | -41.48%1.08B | -30.80%890.07M | 28.54%2.07B | 27.84%2.26B | 47.75%1.85B | 56.56%1.29B | -20.60%1.61B | -11.18%1.77B |
| Add:Non operating Income | -32.72%94.13M | -61.11%27.9M | -73.68%15.74M | -83.15%7.06M | 35.42%139.91M | 3.93%71.74M | 9.40%59.78M | 22.84%41.88M | -36.75%103.31M | -31.62%69.03M |
| Less:Non operating expense | 35.31%17.02M | 108.46%3M | 104.09%1.51M | 493.99%899.51K | 60.81%12.58M | -615.47%-35.5M | -1,351.44%-36.79M | -86.67%151.43K | -35.49%7.82M | 416.27%6.89M |
| Total profit | -58.99%900.61M | -55.72%1.05B | -43.65%1.1B | -32.51%896.23M | 28.81%2.2B | 29.35%2.37B | 49.30%1.95B | 55.41%1.33B | -21.73%1.7B | -12.44%1.83B |
| Less:Income tax cost | -39.41%252.75M | -57.50%187.99M | -42.98%216.54M | -36.24%177.28M | 42.13%417.18M | 32.12%442.33M | 54.30%379.78M | 46.57%278.06M | -28.70%293.53M | -19.01%334.79M |
| Net profit | -63.58%647.86M | -55.32%862.16M | -43.81%880.14M | -31.52%718.95M | 26.04%1.78B | 28.74%1.93B | 48.14%1.57B | 57.93%1.05B | -20.10%1.41B | -10.82%1.5B |
| Net profit from continuing operation | -63.58%647.86M | -55.32%862.16M | -43.81%880.14M | -31.52%718.95M | 26.04%1.78B | 28.74%1.93B | 48.14%1.57B | 57.93%1.05B | -20.09%1.41B | -10.82%1.5B |
| Less:Minority Profit | -115.32%-4.97M | -122.70%-6.45M | -151.94%-10.89M | -137.27%-7.6M | 27.66%32.44M | 68.42%28.43M | 133.21%20.97M | 1,087.53%20.39M | 106.21%25.41M | -5.28%16.88M |
| Net profit of parent company owners | -62.62%652.83M | -54.31%868.61M | -42.34%891.03M | -29.43%726.56M | 26.01%1.75B | 28.28%1.9B | 47.41%1.55B | 55.27%1.03B | -20.99%1.39B | -10.88%1.48B |
| Earning per share | ||||||||||
| Basic earning per share | -62.14%0.39 | -54.46%0.51 | -42.86%0.52 | -29.51%0.43 | 25.61%1.03 | 28.74%1.12 | 46.77%0.91 | 56.41%0.61 | -22.64%0.82 | -13.86%0.87 |
| Diluted earning per share | -63.11%0.38 | -54.46%0.51 | -42.86%0.52 | -29.51%0.43 | 27.16%1.03 | 28.74%1.12 | 46.77%0.91 | 56.41%0.61 | -22.86%0.81 | -13.00%0.87 |
| Other composite income | -164.66%-28.44M | 95.00%-2.75M | -186.94%-33.71M | -80.37%-91.49M | -31.63%43.98M | -248.62%-54.96M | 171.09%38.77M | -192.48%-50.72M | 127.77%64.32M | 117.22%36.98M |
| Other composite income of parent company owners | -164.66%-28.44M | 95.00%-2.75M | -186.94%-33.71M | -80.37%-91.49M | -31.63%43.98M | -248.62%-54.96M | 171.09%38.77M | -192.48%-50.72M | 127.77%64.32M | 117.22%36.98M |
| Total composite income | -66.02%619.43M | -54.15%859.41M | -47.27%846.43M | -37.20%627.47M | 23.53%1.82B | 22.06%1.87B | 49.78%1.61B | 38.85%999.19M | -3.85%1.48B | 4.77%1.54B |
| Total composite income of parent company owners | -65.12%624.4M | -53.10%865.87M | -45.88%857.32M | -35.12%635.07M | 23.45%1.79B | 21.54%1.85B | 49.07%1.58B | 36.34%978.8M | -4.74%1.45B | 4.89%1.52B |
| Total composite income of minority owners | -115.32%-4.97M | -122.70%-6.45M | -151.94%-10.89M | -137.27%-7.6M | 27.66%32.44M | 68.42%28.43M | 133.21%20.97M | 1,087.53%20.39M | 106.21%25.41M | -5.28%16.88M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- |
| Auditor | Huaxing Certified Public Accountants Firm (Special General Partnership) | -- | -- | -- | Huaxing Certified Public Accountants Firm (Special General Partnership) | -- | -- | -- | Huaxing Certified Public Accountants Firm (Special General Partnership) | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.